S&P Futures
3,899.25 -17.00 (-0.43%) Dow Futures
31,358.00 -129.00 (-0.41%) Nasdaq Futures
12,088.25 -52.25 (-0.43%) Russell 2000 Futures
1,753.20 -8.50 (-0.48%) Crude Oil
105.81 -1.81 (-1.68%) Gold
1,831.90 +1.60 (+0.09%)
Vir Biotechnology, Inc. (VIR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 25.89 |
| Open | 25.89 |
| Bid | 24.90 x 800 |
| Ask | 25.50 x 800 |
| Day's Range | 24.75 - 26.04 |
| 52 Week Range | 18.21 - 58.00 |
| Volume | |
| Avg. Volume | 1,645,340 |
| Market Cap | 3.288B |
| Beta (5Y Monthly) | -0.58 |
| PE Ratio (TTM) | 2.76 |
| EPS (TTM) | 8.99 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.71 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VIR
Related Research
- Vir Biotechnology, Inc.VIR: Lowering target price to $20.00VIR BIOTECHNOLOGY INC has an Investment Rating of SELL; a target price of $20.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.RatingFair ValueEconomic Moat5 days agoArgus Research
- GlobeNewswire
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June – SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an
- Motley Fool
Buy the Dip on These 3 Healthcare Stocks
With the S&P 500 down over 23% year to date, investors looking for safety are eyeing the healthcare industry. Taylor Carmichael (Vir Biotechnology): Vir Bio is down about 45% in 2022, but it is one of my highest-confidence positions in healthcare right now. When the Food and Drug Administration gave Vir -- and its partner, GlaxoSmithKline -- an Emergency Use Authorization (EUA) for its COVID-19 treatment sotrovimab (trademark Xevudy), demand for the drug skyrocketed.
- GlobeNewswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster presentations at the International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place in London and online June 22-26. The oral presentation will highlight new dose and duration data from a Phase 2
